Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344947 | 1.00 | PDE8B (0.49) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL80021 | 1.00 | PDE8B (0.49) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL20214777 | 0.98 | PDE8B (0.48) | PDE8BKDM1AATMHSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL3564519 | 0.98 | PDE8B (0.48) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL20186804 | 0.98 | PDE8B (0.48) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL337349 | 0.95 | HSD17B10 (0.48) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL337037 | 0.95 | HSD17B10 (0.48) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL205359 | 0.95 | HSD17B10 (0.48) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1027414 | 0.94 | HSD17B10 (0.47) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1026857 | 0.94 | HSD17B10 (0.47) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20250376450-A1 | COMPOUNDS AND COMPOSITIONS FOR EYE TREATMENTS | AVEDRO INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS LLC (US) | 2025-09-25 | — | — | US | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025111409-A1 | HETEROCYCLIC COMPOUNDS OF FORMULA (I) FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY VIA MODULATION OF SMN2 SPLICING | BIOGEN MA INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4526292-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | Biogen MA Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELLTAXIS, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| CN-115894447-B | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-4364804-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica NV (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-02 | — | — | US | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
| US-20030073691-A1 | Polycyclic compounds | HOFFMANN-LA ROCHE INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003031444-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
| EP-1289955-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2003004467-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| WO-2001096302-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-12-20 | — | — | WO | disclosed |
| EP-0839145-A1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003071-A1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073691-A1 | Polycyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, PKD1 | PDE8B 4791/4885KDM1A 1402/4885ATM 2703/4885 |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | PDE8B 1049/4885KDM1A 1493/4885ATM 437/4885 |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | PDE8B 2120/4885KDM1A 1980/4885ATM 3685/4885 |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | PDE8B 1663/4885KDM1A 2027/4885ATM 4561/4885 |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | PDE8B 1663/4885KDM1A 2027/4885ATM 4561/4885 |
| US-20250376450-A1 | COMPOUNDS AND COMPOSITIONS FOR EYE TREATMENTS | PLK3, EYA3, PLK4 | PDE8B 1587/4885KDM1A 2730/4885ATM 199/4885 |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | HCRTR2, HCRTR1, NPSR1 | PDE8B 4562/4885KDM1A 1254/4885ATM 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.